These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37606858)

  • 41.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Anticancer Res; 2023 Jan; 43(1):127-136. PubMed ID: 36585209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Value of Semiquantitative Parameters Derived from
    Urso L; Evangelista L; Alongi P; Quartuccio N; Cittanti C; Rambaldi I; Ortolan N; Borgia F; Nieri A; Uccelli L; Schirone A; Panareo S; Arnone G; Bartolomei M
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer.
    Sasada S; Kimura Y; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Anticancer Res; 2020 Jun; 40(6):3395-3400. PubMed ID: 32487636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Pretreatment
    Yao J; Wang Y; Lin Y; Yang Y; Wan J; Gong X; Zhang F; Zhang W; Marks T; Wang S; Jin H; Shan H
    Drug Des Devel Ther; 2021; 15():4157-4166. PubMed ID: 34621120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.
    Kaya S; Aktas B; Tanrikulu Sismek E; Akif Ozturk M; Dede F; Kaya H; Ugurlu U; Ozgen Z; Koca S; Halil S; Hasanov R; Alan O; Akgul Babacan N; Ercelep O; Dane F; Gumus M; Yumuk F
    J BUON; 2017; 22(5):1191-1198. PubMed ID: 29135102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
    Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive value of
    Başoğlu T; Özgüven S; Özkan HŞ; Çınar M; Köstek O; Demircan NC; Arıkan R; Telli TA; Ercelep Ö; Kaya H; Öneş T; Erdil TY; Uğurlu MÜ; Dane F; Yumuk PF
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(3):171-178. PubMed ID: 35577492
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
    Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic impact of
    François C; Mailliez A; Chretien S; Leguillette C; Oudoux A; Ceugnart L; Barthoulot M; Cougnenc O; Olivier A
    Breast Cancer Res Treat; 2024 Oct; 207(3):551-559. PubMed ID: 38837087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
    J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.